Beam Therapeutics

Historical price data

Beam Therapeutics is a clinical-stage biotechnology company developing a new class of precision genetic medicines based on its foundational base editing technology. The company's approach allows for the correction of point mutations, insertion or deletion of single bases, and modulation of gene expression with high efficiency and specificity. Beam is advancing a diversified pipeline of in vivo and ex vivo programs targeting sickle cell disease, alpha-1 antitrypsin deficiency, glycogen storage disease 1a, and various cancers. The company has established strategic collaborations with leading pharmaceutical partners and went public in February 2020.

Base editing technology enabling precise, programmable single-letter changes to DNA without creating double-strand breaks, allowing for correction of point mutations, gene modulation, and targeted knockouts with high specificity and efficiency.

7 drugs in pipeline

Total raised: $402M

Beam faces competition from CRISPR Therapeutics/Vertex in ex vivo gene editing for hematological diseases, Intellia Therapeutics in in vivo CRISPR therapies, and several other gene editing companies. Beam differentiates through its base editing technology's precision advantages, broad pipeline spanning both in vivo and ex vivo approaches, and proprietary delivery capabilities.